The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.

<h4>Background</h4>Glial fibrillary acidic protein (GFAP) is a specific intermediate filament of the cytoskeleton of the astrocyte and may be used as a specific marker for astrocytic damage. It is detectable in the cerebrospinal fluid following a relapse caused by Multiple Sclerosis (MS)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mithu Storoni, Axel Petzold, Gordon T Plant
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5cd30cbea96c47ef9541b7c31f50deaa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5cd30cbea96c47ef9541b7c31f50deaa
record_format	dspace
spelling	oai:doaj.org-article:5cd30cbea96c47ef9541b7c31f50deaa2021-11-18T06:47:40ZThe use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.1932-620310.1371/journal.pone.0023489https://doaj.org/article/5cd30cbea96c47ef9541b7c31f50deaa2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21876753/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Glial fibrillary acidic protein (GFAP) is a specific intermediate filament of the cytoskeleton of the astrocyte and may be used as a specific marker for astrocytic damage. It is detectable in the cerebrospinal fluid following a relapse caused by Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) spectrum disease. Higher levels are found following an NMO-related relapse. It is not known if GFAP is also detectable in the serum following such relapses. In particular, it is not known if lesions limited to the optic nerve release GFAP in sufficient quantities to be detectable within the serum. The aim of this study was to ascertain the extent to which serum GFAP levels can distinguish between an episode of optic neuritis (ON) related to NMO spectrum disease and ON from other causes.<h4>Methodology/principal findings</h4>Out of 150 patients consecutively presenting to our eye hospital over the period March 2009 until July 2010, we were able to collect a serum sample from 12 patients who had presented with MS-related ON and from 10 patients who had presented with NMO spectrum disease-related ON. We also identified 8 patients with recurrent isolated ON and 8 patients with a corticosteroid-dependent optic neuropathy in the absence of any identified aetiology. GFAP was detectable in the serum of all but three patients (two patients with MS-related ON and one with recurrent optic neuritis). The median serum GFAP level in the patient group with NMO spectrum disease was 4.63 pg/mL whereas in all other cases combined together, this was 2.14 pg/mL. The difference was statistically significant (P = 0.01). A similar statistically significant difference was found when cases with pathology limited to the optic nerve were compared (P = 0.03).<h4>Conclusions</h4>Glial pathology in NMO related optic neuritis is reflected in elevated serum GFAP levels independently of whether or not there is extra-optic nerve disease.Mithu StoroniAxel PetzoldGordon T PlantPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 8, p e23489 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mithu Storoni Axel Petzold Gordon T Plant The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
description	<h4>Background</h4>Glial fibrillary acidic protein (GFAP) is a specific intermediate filament of the cytoskeleton of the astrocyte and may be used as a specific marker for astrocytic damage. It is detectable in the cerebrospinal fluid following a relapse caused by Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) spectrum disease. Higher levels are found following an NMO-related relapse. It is not known if GFAP is also detectable in the serum following such relapses. In particular, it is not known if lesions limited to the optic nerve release GFAP in sufficient quantities to be detectable within the serum. The aim of this study was to ascertain the extent to which serum GFAP levels can distinguish between an episode of optic neuritis (ON) related to NMO spectrum disease and ON from other causes.<h4>Methodology/principal findings</h4>Out of 150 patients consecutively presenting to our eye hospital over the period March 2009 until July 2010, we were able to collect a serum sample from 12 patients who had presented with MS-related ON and from 10 patients who had presented with NMO spectrum disease-related ON. We also identified 8 patients with recurrent isolated ON and 8 patients with a corticosteroid-dependent optic neuropathy in the absence of any identified aetiology. GFAP was detectable in the serum of all but three patients (two patients with MS-related ON and one with recurrent optic neuritis). The median serum GFAP level in the patient group with NMO spectrum disease was 4.63 pg/mL whereas in all other cases combined together, this was 2.14 pg/mL. The difference was statistically significant (P = 0.01). A similar statistically significant difference was found when cases with pathology limited to the optic nerve were compared (P = 0.03).<h4>Conclusions</h4>Glial pathology in NMO related optic neuritis is reflected in elevated serum GFAP levels independently of whether or not there is extra-optic nerve disease.
format	article
author	Mithu Storoni Axel Petzold Gordon T Plant
author_facet	Mithu Storoni Axel Petzold Gordon T Plant
author_sort	Mithu Storoni
title	The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
title_short	The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
title_full	The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
title_fullStr	The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
title_full_unstemmed	The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
title_sort	use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/5cd30cbea96c47ef9541b7c31f50deaa
work_keys_str_mv	AT mithustoroni theuseofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis AT axelpetzold theuseofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis AT gordontplant theuseofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis AT mithustoroni useofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis AT axelpetzold useofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis AT gordontplant useofserumglialfibrillaryacidicproteinmeasurementsinthediagnosisofneuromyelitisopticaspectrumopticneuritis
_version_	1718424352874037248

The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.

Ejemplares similares